Weave Bio Establishes Inaugural Strategic Advisory Board to Shape the Future of AI-Driven Regulatory Science
Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem.
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase
Weave Bio, the leader in AI-native regulatory automation, today announced the launch of HAQ Manager, a breakthrough capability that applies artificial intelligence (AI) and workflow automation to accelerate responses to Health Authority Questions (HAQs) during regulatory review. This launch extends Weave's platform beyond submission preparation into the critical post-submission review phase, helping organizations navigate one of the most time-pressured and consequential stages of drug development.
Weave Bio Secures $20M Series A Funding to Enhance Its AI-Native Regulatory Platform
Weave Bio, a pioneer in AI-native regulatory automation management solutions, today announced its $20 million Series A funding, bringing the company’s total capital raised to $36 million. The round was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
Weave Bio Earns the 2024 “BioTech AI Innovation Of The Year” Award
Weave Bio, an AI-native life sciences platform company, today announced that its AutoIND solution has received the “BioTech AI Innovation of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
Weave Bio Announces $10M in New Funding and Launch of Its AI-Powered Platform to Streamline Drafting, Reviewing & Submitting Regulatory Documents in Drug Development
Weave Bio, an AI-native life sciences platform company, announced the public release of its flagship offering, AutoIND, and seed funding of $10M co-led by Innovation Endeavors and Magnetic Ventures. AutoIND automates and accelerates the preparation, writing, and review process for INDs, and it is the first offering on Weave’s comprehensive Regulatory Automation and Lifecycle Management (ReALM) platform.
